NASDAQ:JUNO

1877 Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$86.96
0.00 (0.00 %)
(As of 03/6/2018)
Add
Today's Range
$86.96
Now: $86.96
$86.96
50-Day Range
$86.96
MA: $86.96
$86.96
52-Week Range
$19.62
Now: $86.96
$87.01
Volume2 shs
Average Volume5.48 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.
1877 logo

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:JUNO
CUSIPN/A
Phone+1-206-5821600
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableOptionable

Headlines

The Inflation Problem For Investors, And Solutions
April 14, 2021 |  seekingalpha.com
Vaccine Efficacy Questions
April 13, 2021 |  seekingalpha.com
Tradeweb Government Bond Update - March 2021
April 13, 2021 |  seekingalpha.com
Dividend Stock Purchase: Lanny's March 2021 Summary
April 13, 2021 |  seekingalpha.com
Value And Dividends: A Rising Tide
April 13, 2021 |  seekingalpha.com
Commodities Rewired
April 13, 2021 |  seekingalpha.com
AstraZeneca/Oxford Calculations
April 13, 2021 |  seekingalpha.com
See More Headlines

MarketRank

Overall MarketRank

0.87 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Receive JUNO News and Ratings via Email

Sign-up to receive the latest news and ratings for JUNO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











1877 (NASDAQ:JUNO) Frequently Asked Questions

What stocks does MarketBeat like better than 1877?

Wall Street analysts have given 1877 a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 1877 wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were 1877's earnings last quarter?

1877 (NASDAQ:JUNO) issued its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.80) by $0.07. The biopharmaceutical company earned $44.80 million during the quarter, compared to analysts' expectations of $18.12 million. The company's quarterly revenue was up 115.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.57) earnings per share.
View 1877's earnings history
.

Who are 1877's key executives?

1877's management team includes the following people:
  • Howard H. Pien, Independent Chairman of the Board (Age 59)
  • Hans Edgar Bishop, President, Chief Executive Officer, Director (Age 53)
  • Sunil Agarwal M.D., President of Research & Development (Age 47)
  • Steven D. Harr M.D., Chief Financial Officer, Head of Corporate Development (Age 46)
  • Hyam I. Levitsky M.D, Executive vice president - Research, chief scientific officer (Age 54)
  • Robert W. Azelby, Executive Vice President, Chief Commercial Officer (Age 49)
  • Ann Lee Ph.D., Executive Vice President - Technical Operations
  • Patrick Y. Yang, Executive Vice President (Age 69)
  • Cynthia Elkins, Chief Information Officer
  • Bernard J. Cassidy, General Counsel, Secretary (Age 62)

What other stocks do shareholders of 1877 own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 1877 investors own include (CELG), (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), TherapeuticsMD (TXMD), Incyte (INCY), Alibaba Group (BABA) and Heritage-Crystal Clean (HCCI).

When did 1877 IPO?

(JUNO) raised $153 million in an initial public offering (IPO) on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners was co-manager.

What is 1877's stock symbol?

1877 trades on the NASDAQ under the ticker symbol "JUNO."

What is 1877's stock price today?

One share of JUNO stock can currently be purchased for approximately $86.96.

What is 1877's official website?

The official website for 1877 is www.junotherapeutics.com.

Where are 1877's headquarters?

1877 is headquartered at 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States.

How can I contact 1877?

1877's mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States. The biopharmaceutical company can be reached via phone at +1-206-5821600.


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.